Recent Finacing
Recent Raise
Synspira develops inhaled glycopolymer therapeutics to disrupt pulmonary biofilms, reduce mucus viscosity and potentiate antibiotics for CF, COPD and pneumonia; also advancing a non-porcine enzyme replacement for pancreatic insufficiency.
